JP2015520753A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015520753A5 JP2015520753A5 JP2015512120A JP2015512120A JP2015520753A5 JP 2015520753 A5 JP2015520753 A5 JP 2015520753A5 JP 2015512120 A JP2015512120 A JP 2015512120A JP 2015512120 A JP2015512120 A JP 2015512120A JP 2015520753 A5 JP2015520753 A5 JP 2015520753A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treating
- pharmaceutical composition
- composition according
- compound according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261647200P | 2012-05-15 | 2012-05-15 | |
| US61/647,200 | 2012-05-15 | ||
| PCT/GB2013/051233 WO2013171470A1 (en) | 2012-05-15 | 2013-05-14 | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016201383A Division JP6362652B2 (ja) | 2012-05-15 | 2016-10-13 | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015520753A JP2015520753A (ja) | 2015-07-23 |
| JP2015520753A5 true JP2015520753A5 (enExample) | 2016-04-14 |
| JP6027230B2 JP6027230B2 (ja) | 2016-11-16 |
Family
ID=48468659
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015512120A Active JP6027230B2 (ja) | 2012-05-15 | 2013-05-14 | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
| JP2016201383A Active JP6362652B2 (ja) | 2012-05-15 | 2016-10-13 | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016201383A Active JP6362652B2 (ja) | 2012-05-15 | 2016-10-13 | ５−［［４−［［モルホリン−２−イル］メチルアミノ］−５−（トリフルオロメチル）−２−ピリジル］アミノ］ピラジン−２−カルボニトリルおよびその治療上の使用 |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9663503B2 (enExample) |
| EP (2) | EP3210980B1 (enExample) |
| JP (2) | JP6027230B2 (enExample) |
| KR (6) | KR102090792B1 (enExample) |
| CN (2) | CN104302635B (enExample) |
| AU (2) | AU2013261605B2 (enExample) |
| BR (1) | BR112014026801B1 (enExample) |
| CA (1) | CA2870837C (enExample) |
| DK (1) | DK2855448T3 (enExample) |
| ES (2) | ES2624307T3 (enExample) |
| IL (1) | IL235133A (enExample) |
| IN (1) | IN2014DN09221A (enExample) |
| MX (1) | MX358819B (enExample) |
| NZ (1) | NZ702050A (enExample) |
| PL (1) | PL2855448T3 (enExample) |
| RU (1) | RU2659786C2 (enExample) |
| SG (1) | SG11201407238VA (enExample) |
| WO (1) | WO2013171470A1 (enExample) |
| ZA (1) | ZA201408452B (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2776417B1 (en) | 2011-11-09 | 2018-10-31 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| CA2870837C (en) | 2012-05-15 | 2022-05-10 | Cancer Research Technology Limited | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
| PL3808749T3 (pl) | 2012-12-07 | 2023-07-10 | Vertex Pharmaceuticals Incorporated | Pirazolo[1,5-a]pirymidyny użyteczne jako inhibitory kinazy atr do leczenia chorób nowotworowych |
| JP2016512815A (ja) | 2013-03-15 | 2016-05-09 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ａｔｒキナーゼの阻害剤として有用な縮合ピラゾロピリミジン誘導体 |
| PL3077397T3 (pl) | 2013-12-06 | 2020-04-30 | Vertex Pharmaceuticals Inc. | Związek 2-amino-6-fluoro-n-[5-fluoro-pirydyn-3-ylo]pyrazolo [1,5-a]pirymidino-3-karboksamidu przydatny jako inhibitor kinazy atr, jego wytwarzanie, różne postacie stałe i ich radioznakowane pochodne |
| SG10201902206QA (en) | 2014-06-05 | 2019-04-29 | Vertex Pharma | Radiolabelled derivatives of a 2-amino-6-fluoro-n-[5-fluoro-pyridin-3-yl]- pyrazolo[1,5-a]pyrimidin-3-carboxamide compound useful as atr kinase inhibitor, the preparation of said compound and different solid forms thereof |
| PT3157566T (pt) * | 2014-06-17 | 2019-07-11 | Vertex Pharma | Método para tratamento de cancro utilizando uma combinação de inibidores chk1 e atr |
| RU2768621C1 (ru) | 2015-09-30 | 2022-03-24 | Вертекс Фармасьютикалз Инкорпорейтед | Способ лечения рака с использованием комбинации повреждающих днк средств и ингибиторов atr |
| WO2018094325A1 (en) * | 2016-11-18 | 2018-05-24 | The Trustees Of Columbia University In The City Of New York | Therapeutic modulation of oncogenes by pharmacologic top2 targeting for cancer |
| KR20190130621A (ko) * | 2017-03-31 | 2019-11-22 | 시애틀 지네틱스, 인크. | Chk1 저해제와 wee1 저해제의 조합물 |
| US11596637B2 (en) | 2017-04-10 | 2023-03-07 | Sierra Oncology, Inc. | CHK1 (SRA737)/PARPi combination methods of inhibiting tumor growth |
| WO2018191299A1 (en) * | 2017-04-10 | 2018-10-18 | Sierra Oncology, Inc. | Chk1(sra737)wee1 inhibitor combination methods of inhibiting tumor growth |
| AU2018278336A1 (en) * | 2017-06-01 | 2020-01-16 | Crt Pioneer Fund Lp | Biomarkers and patient selection strategies |
| CN107266897B (zh) * | 2017-08-04 | 2019-05-14 | 上海跃贝新材料科技股份有限公司 | 一种低粘度矿物增强pc/pet合金材料及其制备方法 |
| CA3092079A1 (en) * | 2018-02-26 | 2019-08-29 | Sierra Oncology, Inc. | Methods of treatment of cancer comprising chk1 inhibitors |
| CN113631179A (zh) * | 2019-01-25 | 2021-11-09 | 努梅迪公司 | 用于治疗特发性肺纤维化的方法 |
| CA3135165A1 (en) * | 2019-03-28 | 2020-10-01 | Sierra Oncology, Inc. | Methods of treating cancer with chk1 inhibitors |
| CA3140123A1 (en) * | 2019-05-14 | 2020-11-19 | Sierra Oncology, Inc. | Methods of treating cancer using chk1 inhibitors |
| CN110872277B (zh) * | 2019-11-14 | 2021-06-04 | 浙江大学 | N-取代芳环-2-氨基嘧啶类化合物及用途 |
| CN110684083B (zh) * | 2019-12-06 | 2020-05-15 | 北京诺赛启研再生医学研究院有限公司 | 抑制黑色素合成的偶联物ii及其在药品和化妆品中的应用 |
| CN110680928B (zh) * | 2019-12-06 | 2020-04-28 | 深圳前海港影生物科技有限公司 | 抑制黑色素合成的偶联物及其在药品和化妆品中的应用 |
| TW202204348A (zh) * | 2020-04-07 | 2022-02-01 | 美商西爾拉癌症醫學公司 | Ｃｈｋ１抑制劑之合成方法 |
| EP4387959A4 (en) * | 2021-08-17 | 2025-07-02 | Glaxosmithkline Intellectual Property No 3 Ltd | PREPARATION OF A P2X3 ANTAGONIST |
| TW202519226A (zh) | 2023-11-08 | 2025-05-16 | 美商艾克塞里克斯公司 | 使用抑制ｐｋｍｙｔ１之化合物治療癌症之方法 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773778A (en) | 1972-01-24 | 1973-11-20 | Squibb & Sons Inc | Sulfur derivatives of pyrazolo (3,4-b)pyridines |
| IL112248A0 (en) | 1994-01-25 | 1995-03-30 | Warner Lambert Co | Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them |
| ATE212993T1 (de) | 1995-07-06 | 2002-02-15 | Novartis Erfind Verwalt Gmbh | Pyrolopyrimidine und verfahren zu ihrer herstellung |
| CA2464000C (en) | 2001-10-19 | 2011-04-19 | Ortho-Mcneil Pharmaceutical, Inc. | 2-phenyl benzimidazoles and imidazo-[4,5]-pyridines as cdsi/chk2-inhibitors and adjuvants to chemotherapy or radiation therapy in the treatment of cancer |
| EP1441725A1 (en) | 2001-10-26 | 2004-08-04 | Aventis Pharmaceuticals Inc. | Benzimidazoles and analogues and their use as protein kinases inhibitors |
| JP2005515173A (ja) | 2001-10-31 | 2005-05-26 | バイエル・ヘルスケア・アクチェンゲゼルシャフト | ピリミド［４，５−ｂ］インドール誘導体 |
| EP1501514B1 (en) | 2002-05-03 | 2012-12-19 | Exelixis, Inc. | Protein kinase modulators and methods of use |
| AU2003243318A1 (en) * | 2002-05-29 | 2003-12-19 | Millennium Pharmaceuticals, Inc. | Diarylurea compounds and derivatives as chk-1 inhibitors for the treatment of cancer |
| CA2533774A1 (en) | 2003-07-29 | 2005-02-10 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CN1863774B (zh) | 2003-10-08 | 2010-12-15 | Irm责任有限公司 | 用作蛋白激酶抑制剂的化合物和组合物 |
| ATE437872T1 (de) | 2003-10-14 | 2009-08-15 | Univ Arizona | Proteinkinaseinhibitoren |
| CA2542329A1 (en) | 2003-10-16 | 2005-04-28 | Chiron Corporation | 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines as inhibitors of raf kinase for treatment of cancer |
| US7163939B2 (en) | 2003-11-05 | 2007-01-16 | Abbott Laboratories | Macrocyclic kinase inhibitors |
| US20050096324A1 (en) | 2003-11-05 | 2005-05-05 | Zhi-Fu Tao | Macrocyclic kinase inhibitors |
| ATE458730T1 (de) | 2004-04-13 | 2010-03-15 | Icagen Inc | Polycyclische pyrazine als kaliumionenkanal- modulatoren |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| BRPI0609956A2 (pt) | 2005-04-28 | 2010-05-18 | Supergen Inc | inibidores de proteìna quinase |
| AU2006264043B2 (en) | 2005-06-28 | 2012-04-26 | Sanofi-Aventis | Isoquinoline derivatives as inhibitors of Rho-kinase |
| TWI387592B (zh) | 2005-08-30 | 2013-03-01 | Novartis Ag | 經取代之苯并咪唑及其作為與腫瘤形成相關激酶之抑制劑之方法 |
| US7776865B2 (en) | 2005-10-06 | 2010-08-17 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US8119655B2 (en) | 2005-10-07 | 2012-02-21 | Takeda Pharmaceutical Company Limited | Kinase inhibitors |
| GB0616747D0 (en) * | 2006-08-24 | 2006-10-04 | Astrazeneca Ab | Novel compounds |
| EP2125746B1 (en) | 2006-12-27 | 2012-04-18 | Sanofi | Cycloalkylamine substituted isoquinoline derivatives |
| EP2727909A1 (en) * | 2007-03-16 | 2014-05-07 | The Scripps Research Institute | Inhibitors of focal adhesion kinase |
| WO2008117050A1 (en) | 2007-03-27 | 2008-10-02 | Astrazeneca Ab | Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer |
| US8618121B2 (en) | 2007-07-02 | 2013-12-31 | Cancer Research Technology Limited | 9H-pyrimido[4,5-B]indoles, 9H-pyrido[4',3':4,5]pyrrolo[2,3-D]pyridines, and 9H 1,3,6,9 tetraaza-fluorenes as CHK1 kinase function inhibitors |
| GB0719644D0 (en) | 2007-10-05 | 2007-11-14 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB0803018D0 (en) | 2008-02-19 | 2008-03-26 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP2776417B1 (en) | 2011-11-09 | 2018-10-31 | Cancer Research Technology Limited | 5-(pyridin-2-yl-amino)-pyrazine-2-carbonitrile compounds and their therapeutic use |
| CA2870837C (en) | 2012-05-15 | 2022-05-10 | Cancer Research Technology Limited | 5-[[4-[[morpholin-2-yl]methylamino]-5-(trifluoromethyl)-2-pyridyl]amino]pyrazine-2-carbonitrile and therapeutic uses thereof |
-
2013
- 2013-05-14 CA CA2870837A patent/CA2870837C/en active Active
- 2013-05-14 KR KR1020147031572A patent/KR102090792B1/ko active Active
- 2013-05-14 KR KR1020207007411A patent/KR102246265B1/ko active Active
- 2013-05-14 RU RU2014147105A patent/RU2659786C2/ru active
- 2013-05-14 JP JP2015512120A patent/JP6027230B2/ja active Active
- 2013-05-14 WO PCT/GB2013/051233 patent/WO2013171470A1/en not_active Ceased
- 2013-05-14 CN CN201380025541.3A patent/CN104302635B/zh active Active
- 2013-05-14 KR KR1020227037439A patent/KR102635954B1/ko active Active
- 2013-05-14 DK DK13723910.9T patent/DK2855448T3/en active
- 2013-05-14 PL PL13723910T patent/PL2855448T3/pl unknown
- 2013-05-14 SG SG11201407238VA patent/SG11201407238VA/en unknown
- 2013-05-14 EP EP17152400.2A patent/EP3210980B1/en active Active
- 2013-05-14 ES ES13723910.9T patent/ES2624307T3/es active Active
- 2013-05-14 US US14/396,338 patent/US9663503B2/en active Active
- 2013-05-14 KR KR1020247004407A patent/KR20240023685A/ko not_active Withdrawn
- 2013-05-14 NZ NZ702050A patent/NZ702050A/en unknown
- 2013-05-14 ES ES17152400T patent/ES2981584T3/es active Active
- 2013-05-14 BR BR112014026801-0A patent/BR112014026801B1/pt active IP Right Grant
- 2013-05-14 CN CN201610652725.8A patent/CN106279142B/zh active Active
- 2013-05-14 AU AU2013261605A patent/AU2013261605B2/en active Active
- 2013-05-14 KR KR1020217012299A patent/KR102341637B1/ko active Active
- 2013-05-14 KR KR1020217041302A patent/KR20210156333A/ko not_active Ceased
- 2013-05-14 EP EP13723910.9A patent/EP2855448B1/en active Active
- 2013-05-14 IN IN9221DEN2014 patent/IN2014DN09221A/en unknown
- 2013-05-14 MX MX2014012881A patent/MX358819B/es active IP Right Grant
-
2014
- 2014-10-19 IL IL235133A patent/IL235133A/en active IP Right Grant
- 2014-11-18 ZA ZA2014/08452A patent/ZA201408452B/en unknown
-
2016
- 2016-10-13 JP JP2016201383A patent/JP6362652B2/ja active Active
-
2017
- 2017-05-04 US US15/587,270 patent/US10259806B2/en active Active
- 2017-11-28 AU AU2017268508A patent/AU2017268508C1/en active Active
-
2020
- 2020-12-17 US US17/124,606 patent/US11787792B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015520753A5 (enExample) | ||
| RU2014147105A (ru) | 5-[[4-[[морфолин-2-ил]метиламино]-5-(трифторметил)-2-пиридил]амино]пиразин-2-карбонитрил, его терапевтические применения | |
| Hong et al. | Melatonin treatment induces interplay of apoptosis, autophagy, and senescence in human colorectal cancer cells | |
| JP6147799B2 (ja) | Ｐａｒｐインヒビターとの組合せ療法 | |
| Rajawat et al. | Therapeutic targeting of poly (ADP‐ribose) polymerase‐1 (PARP1) in cancer: Current developments, therapeutic strategies, and future opportunities | |
| JP2017036314A5 (enExample) | ||
| TR201807411T4 (tr) | DNA-PK inhibitörleri. | |
| NZ580009A (en) | Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer | |
| JP2016536286A5 (enExample) | ||
| RU2016110874A (ru) | Комбинация ингибитора alk и ингибитора cdk для лечения клеточных пролиферативных заболеваний | |
| PH12016502354A1 (en) | Pharmaceutical composition | |
| JP2016501221A5 (enExample) | ||
| JP2009536156A5 (enExample) | ||
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| JP2017514806A5 (enExample) | ||
| JP2016529285A5 (enExample) | ||
| JP2017526662A5 (enExample) | ||
| JP2016522202A5 (enExample) | ||
| JP2014534269A5 (enExample) | ||
| TW201613589A (en) | Combination methods for treating cancers | |
| Gorjánácz | Nuclear assembly as a target for anti-cancer therapies | |
| JP2013507453A5 (enExample) | ||
| JP2014512355A5 (enExample) | ||
| JP2014532751A5 (enExample) | ||
| JP2018062523A5 (enExample) |